STERIS plc

- The company ended fiscal 2026 with a strong balance sheet and total debt of $1.9 billion. - Gross debt to EBITDA at year-end was approximately 1.2x, well below the company's target range of 2 to 2.5x. - Fiscal 2027 guidance anticipates capital expenditures of $375 million and free cash flow of $850 million. - There is no specific mention of new fundraising through debt or equity in the call transcript. - The company plans to use excess cash primarily for share buybacks ($200 million to $300 million annually), dividend increases, reinvestment in the business, and M&A. - Additional withholding tax from capital deployment priorities is expected to put upward pressure on the tax rate. - Overall, the company appears financially strong and expects to fund priorities through operating cash flow and existing capital rather than new debt or equity fundraising.

- Fiscal 2027 CapEx planned at $375 million. - New sterility assurance manufacturing plant to be built in Mentor, Ohio. - Investment of about $60 million over 2 years. - Facility expected operational by end of calendar 2027. - Will consolidate existing U.S. production into a state-of-the-art manufacturing center of excellence. - Continued investment in AST expansion projects, particularly for x-ray globally. - Multiyear project kickoff to support service workflows with upgraded AI technologies aimed at improving quality, productivity, and customer experience in Healthcare and Life Sciences segments. - Capital spending priorities shifting as AST X-ray expansion nears completion. - The company expects to continue investing in organic growth as well as through tuck-in acquisitions in Healthcare.

- Fiscal 2027 as-reported revenue expected to grow 7% to 8%. - Constant currency organic revenue growth anticipated at 6% to 7% for the total company. - Segment growth outlook: - Healthcare and Life Sciences: 6% to 7% constant currency organic growth. - Advanced Sterilization Products (AST): 7% to 8% growth, starting more conservatively. - U.S. procedure volume expected to grow mid-single digits consistently in fiscal 2027. - Inventory levels managed carefully by med tech customers, causing cautious outlook for AST early in the year. - Procedure rates and patient demand remain consistent, supporting volume growth. - Capital equipment revenue and backlog expected to progress positively, with some lumpiness typical. - Long-term organic mid-to-high single-digit growth target, aiming for double-digit bottom line growth.

- Fiscal 2027 earnings per share (EPS) outlook: $11.10 to $11.30, reflecting 9% to 11% growth over fiscal 2026. - EBIT margins anticipated to expand approximately 50 basis points at the high end of the range. - Revenue growth expected at 7% to 8% as reported; 6% to 7% constant currency organic revenue growth for Healthcare and Life Sciences; 7% to 8% for AST (with a conservative start). - Double-digit bottom-line growth targeted over time, supported by mid- to high-single-digit organic revenue growth. - Free cash flow expected at $850 million with CapEx of $375 million in fiscal 2027. - Operational improvements and increased sales of higher-margin consumables will drive margin expansion. - Incremental investments planned in upgraded AI technologies to improve service workflows and customer experience.

- Capital equipment backlog ended solidly at just under $100 million (Page 3). - Healthcare capital equipment backlog ended just under $400 million with orders up 2% in Q4 (Page 3). - Orders have remained solid going forward despite pressures on healthcare systems (Page 7). - No explicit mention of total current orderbook combining all segments but backlog levels indicate strong pending orders, particularly in Healthcare capital equipment.